Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334707 | 0.88 | NPC1 (0.39) | KMT2AEIF2AK3GRM5NPC1 | |
| SCHEMBL12307454 | 0.83 | TP53 (0.40) | ALDH1A1KMT2APOLBGRM5 | |
| SCHEMBL12307442 | 0.82 | GRM5 (0.39) | KDM4EALDH1A1KMT2AGRM5NPC1 | |
| SCHEMBL12334300 | 0.80 | GRM5 (0.39) | KDM4EALDH1A1KMT2AGRM5NPC1 | |
| SCHEMBL12307472 | 0.79 | MAPT (0.40) | KDM4EALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL12307452 | 0.79 | NPC1 (0.40) | MAPK1ALDH1A1POLBGRM5NPC1 | |
| SCHEMBL12307449 | 0.79 | SMN1; SMN2 (0.35) | GRM5 | |
| SCHEMBL12307528 | 0.77 | RBP4 (0.39) | ALDH1A1KMT2ARAB9A | |
| SCHEMBL12307477 | 0.77 | SIGMAR1 (0.44) | ALDH1A1KMT2AKCNQ2POLBGRM5 | |
| SCHEMBL12307456 | 0.77 | SMN1; SMN2 (0.33) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2327704-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | Shionogi&Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R5, PIK3R4, PIK3R1 | MAPK1 122/4885KDM4E 1658/4885ALDH1A1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.